Founded by former executives of HCV companies that scored big exits, Antios Therapeutics Inc. (Atlanta, Ga.) raised a $25 million series A round to develop a cure for HBV. Antios' co-founders include CEO Abel De...

Founded by former executives of HCV companies that scored big exits, Antios Therapeutics Inc. raised a $25 million series A round to develop a cure for HBV. Antios' co-founders include CEO Abel De La Rosa...

Merck & Co. Inc. (NYSE:MRK) discontinued development of MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir), emptying its pipeline of candidates to treat HCV infection. The pharma based its decision on a review of Phase II efficacy data...

Merck & Co. Inc. (NYSE:MRK) discontinued development of MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir), emptying its pipeline of candidates to treat HCV infection. The pharma based its decision on a review of Phase II efficacy data...

Merck & Co. Inc. (NYSE:MRK) discontinued development of MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir), emptying its pipeline of candidates to treat HCV infection. The pharma based its decision on a review of Phase II efficacy data...

In an SEC filing, Merck said it would record a pretax impairment charge of $2.9 billion for HCV candidate uprifosbuvir ( MK-3862 ) based on "recent changes to the product profile, as well as changes to its...

A shifting HCV market and pricing pressure caused Merck & Co. Inc. (NYSE:MRK) to dramatically reduce its expectations for uprifosbuvir (MK-3862), which the pharma gained in its $3.9 billion acquisition of Idenix Pharmaceuticals Inc. in...

A federal jury ordered Gilead to pay Merck $2.5 billion in damages in an HCV patent infringement lawsuit. According to the jury's verdict, the damages are based on a 10% royalty rate for Gilead's U.S....

A federal jury ordered Gilead Sciences Inc. (NASDAQ:GILD) to pay Merck & Co. Inc. (NYSE:MRK) $2.5 billion in damages in an HCV patent infringement lawsuit. According to the jury's verdict, the damages are based on...

An abstract released ahead of next month's American Association for the Study of Liver Diseases (AASLD) meeting describes Phase II findings across multiple HCV genotypes produced by eight weeks of treatment with a once-daily regimen...